By bizzy.fain@gmail.com on Tue, 09/29/2020 - 14:13 Phone 1-866-522-8894 Email medinfo@oncopeptides.com ClinicalTrials.gov URL https://clinicaltrials.gov/ct2/results?recrs=&cond=&term=Oncopeptides+AB+&cntry=&state=&city=&dist= NCT Name NCT04534322 Acknowledgement 24 hours EA Page https://oncopeptides-us.com/en/expanded-access-program/ Sponsor Oncopeptides AB Expanded Access Listings Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma Conditions Relapsed and/or Refractory Multiple Myeloma To provide early treatment access and evaluate the safety of melflufen and dexamethasonein patients with triple class refractory (TCR) multiple myeloma (MM).
